Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: R03BB06

Enurev Breezhaler(glycopyrronium bromide)

Pulmonary Disease, Chronic Obstructive

Marketing Authorisation Holder: Novartis Europharm Ltd

EMA Authorisation: 28/09/2012

INN: glycopyrronium bromide

Indication

Enurev Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Enurev Breezhaler — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.